Journal of Biomedical Sciences | ISSN: 2960-9356
Research Article Peer-review, Open Access

Medicines Used for Oncological Diseases and Remedies against Malignant Tumors

Sokhib Rashidov Zamon o‘g‘li [1]

Raufjon Usmonov Rajabboy o’g’li [2]

Bekzodkhon Buzrukov Jamshedkhon o‘g‘li [3]

Firdavs Boboqulov Khurshid o'g'li [4]

Abstract

Every year, millions of people die from cancer, an aberrant state of cells that produces aggressive tumors and unchecked cell proliferation. The development of numerous new treatment regimens and their subsequent trials are a result of our growing understanding of the disease and its molecular mechanism or mechanisms. Many therapy combinations have been proposed in the last few decades and are currently being used to treat a variety of malignancies. A few years ago, targeted drug therapy, immunotherapy, and tailored medications were uncommon. Today, they are widely used. As cancer type-specific biomarkers are being discovered and various cancer kinds are currently receiving systematic medicines that increase patients' disease-free survival, the area of cancer discoveries and therapeutics is rapidly changing. Chemotherapy is still a commonly used therapeutic option despite its recognized negative effects on the physical and mental health of patients, despite mounting research that suggests a systematic and focused strategy may be the way of the future for cancer treatment. Over the past few decades, chemotherapy and medicines have been the first line of treatment for advanced cancers when surgery and/or radiation therapy are not appropriate for certain reasons. The current report briefly summarizes the current and recent developments in chemotherapy and evaluates the state of the enrolled medications. It also thoroughly examines the growing significance of targeted and specific therapeutic approaches currently being used to improve clinical outcomes and survival rates for cancer patients.

Keywords: Antimicrobial peptides, immunotherapy, combination therapy, cancer treatments, clinical trials, patient survival, personalized medicine, targeted medication administration.

[1,2,3,4] Department of pharmacology of Tashkent medical academy

Introduction. A number of genetic and molecular changes lead to the unchecked development and proliferation of cells in cancer, a disease that is diverse and complex. As a result, the tissue mass in the affected areas of the body rapidly increases. Under normal circumstances, a cell receives signals to die and to be replaced by a new, healthier cell. Other cells are deprived of regular supplements and growth nutrients while cancer cells proliferate by consuming the body's oxygen and vitamins. These cells have the ability to manipulate the microenvironment to their advantage, trick the body's immune system, and take advantage of other cells' physiology to suit their requirements. Three things happened in the last century that contributed to the development of cancer treatment: Wilhelm Konrad Roentgen's discovery of X-rays, Halsted's invention of the first surgical technique, and the use of transplantable animal tumor models in cancer research [1-7]. Paul Ehrlich, a German chemist who studied the use of medications to treat infectious disorders, originally came up with the term "chemotherapy." He was also the first scientist to test a number of compounds for their disease-fighting properties using animal models. The usage of arsenicals appears to have begun in the 1900s, according to historical records. In the 1960s, surgery and radiation therapy were the cornerstones of cancer treatment. Combination chemotherapy began to gain importance when micrometastases and the recurrence of cancer following surgery and radiation therapy became apparent. Cancer has become a serious public health concern. Every day, more than 52,900 people receive a cancer diagnosis, and the disease claims the lives of more than 27,000 people. Globally, there are predicted to be 16.2 million fatalities and 28 million new cases by 2040. Increased investment in developing cancer drug development and the broad use of targeted, customized treatment are the best ways to consistently lower the death rate from cancer worldwide [8-12]. The chronology of cancer treatments shows how therapies have changed throughout the previous 170 years, emphasizing the ground-breaking methods that have been developed to improve clinical results and patients' quality of life. Mesothelin, osteopontin, legumain, carcinoembryonic antigen (CEA), human epididymis protein 4 (HE4), and vitamin E-binding plasma protein are a few of the biomarkers that are now being utilized to diagnose cancer. Over the years, numerous anti-cancer medications and natural medicinal substances have been developed that can inhibit tumor growth in a variety of ways. Certain medications or substances affect important biological enzymes, while others might change how cells metabolize. They have also demonstrated the ability to disrupt a number of vital biological functions, such as immunological responses, drug resistance, DNA damage, apoptosis, and programs for cell death. Although these medications have unique mechanisms of action and are selective for a variety of cancer types, their anti-cancer efficacy could be eliminated by a minor change to their molecular makeup [13-19]. Following reports of mustard gas harming bone marrow and lymphatic tissues, the concept of chemotherapy—using toxic substances and medications to target malignant cells—was born. Later, employing an efficient gas derivative (nitrogen mustard), the effects were confirmed in mice, demonstrating a successful regression of lymphoma tissues. The main way that chemotherapy functions is by preventing the cancer cells from proliferating and dividing further. Compared to normal cells, cancer cells often reproduce and develop significantly more quickly, and they also have very high levels of endogenous stress. As a result, the medications can kill them faster and more efficiently than other nearby cells. The kind and stage of cancer are the primary factors that determine which chemopreventive medications or a combination of medications are chosen [20,21,22, 23]. Neutralizing the malignant cells and reducing the stress brought on by the tumor's growth are the main goals of these medications. Two crucial factors to take into account are the treatment's duration and dosage. It has been noted that the drugs are administered at extremely high dosages, which might damage other healthy cells and result in a variety of adverse effects. This paper primarily examines many facets of cancer chemotherapy, including different uses of currently available medications and chemotherapeutic agents. Additionally, by concentrating on targeted medication therapy, immunotherapy, personalized, and integrative medicines, we gave a brief overview of recent developments in interventional techniques and briefly addressed a number of side effects and disadvantages of these treatment approaches [1,2,3,17,18,19,20,21,25].

The main purpose of this presented analytical manuscript is to provide a brief overview of drugs used to treat cancer and anti-malignant tumors.

What is currently known about chemotherapeutics for cancer? Around 400 BC, the father of medicine, Hippocrates, was aware that cancer was a sickness. Because cancer tissue growths resemble crabs, he later came up with the term "carcinos." Later, Celsus substituted the Latin word cancer for the phrase. Numerous ancient works of literature have detailed various human cancers, and the literature of that time period also reveals that various therapeutic modalities were employed in various regions of the ancient world. However, until the turn of the 20th century, the development of methods to treat the illness was essentially stagnant. Greek doctors employed a botanical extract called Colchicum autumnale to dissolve the tumor mass. It's interesting to note that colchicine, the extract's active ingredient, was discovered to have the ability to disrupt microtubule assembly and might be used as a medication in the 1930s. 40 Other comparable substances that were long recognized in medicine as potential anti-tumor medicines include vincristine and vinblastine [11-18]. Numerous mutations, external stimuli (toxic chemicals, viruses, etc.), metabolic changes, etc., have been noted as the root causes of cancer in a number of papers from the second half of the 20th century. The discovery of numerous cellular pathways impacted by different types of cancer has provided a variety of molecular options for targeting and creating potent medications. Depending on the kinds and stages of the cancer that has been detected, a number of drug administration techniques have also been proposed and tested. The existing prescription treatments are discussed here, and then we go back to the chemotherapeutic agents that have significantly advanced the field and improved the lives of millions of people over the past few decades [1,2,3,14,15,17].

Targeted medication administration. The primary flaw in the majority of chemotherapeutic treatment regimens is their lack of specificity, or the incapacity to identify and specifically target malignant cells. As a result, the inability to deliver medications locally to the cancer tissue mass represents a significant therapeutic constraint due to this lack of specificity. Numerous novel strategies have been developed and tested in recent decades, raising expectations for medication delivery in the future. Targeted antibodies, aptamer functionalization, nanoparticle-based delivery systems, and certain medications like Herceptin (for breast cancer) have all shown promise and could be very successful in the years to come. At the forefront of targeted drug delivery techniques are cancer cell-directed antibodies, which have sped up the search for better or maybe improvised strategies [18-26]. The distribution of therapeutic molecules to cancer cells has also been enhanced by various nanocarrier types and nanodrug formulations. The ability to reduce the massive drug-mediated toxicities on other nearby tissues and organs is the main benefit of focused medication delivery. The majority of collateral damage that results in stress and organ breakdowns can also be prevented. However, clinical research is still being done to determine how successful many of these delivery techniques are in patients. The previously released reports contain more information on these delivery mechanisms [1-11].

Immunotherapy. Another very specialized and generally promising strategy to deal with the issue of late-stage cancer treatments is to strengthen our immune system by developing immunotherapy techniques. Over the past ten years, a number of novel strategies have been created to alter and teach a patient's immune system to recognize various cell surface indicators in order to seek out, recognize, and attack the altered cells inside the body. For example, adding immunotherapy to the treatment regimen has greatly increased the success rate of chemotherapeutic medications in treating a variety of cancer types, particularly triple-negative breast tumors. To improve therapeutic results, immunotherapy medications are administered either by alone or in conjunction with chemotherapy medications [11,12,13,14,]. Vaccines, both preventive and therapeutic, have been created to teach patients' immune systems how to fight off the altered cells. One anti-cancer immune medication that aids in the removal of difficult-to-treat breast tumors is atezolizumab. Tisagenlecleucel is an FDA-approved medication that efficiently modifies the patient's chimeric T cell receptor (CAR-T) to treat B-cell lymphoblastic leukemia. Interleukins and interferons are also used in some treatment schemes to strengthen the patient's immune system and accelerate the fight against cancer cells. Furthermore, immunotherapy is a rapidly developing field that is outside the purview of this article [1,2,3,4,9,12].

Combination therapy may combine the long-lasting effects of immunotherapy with the quick tumor shrinkage of targeted medicines. 235 In cases where prolonged host responses targeting numerous antigens may lower the chance of producing potentially fatal drug-resistant clones, immunotherapy may be able to combine the spectacular tumor responses obtained with targeted therapy into long-lasting, durable remissions. One strategy to prevent T cell anergy is to combine cancer vaccines with immune checkpoint inhibitors (ICIs), such as those that target cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1). Moreover, targeted medications that alter the tumor endothelium may promote T-cell and NK-cell invasion [1,2,3,9,13,14]. Hepatotoxicity has been identified as a serious problem in a number of studies that combine immunotherapy with molecularly targeted treatment, either concurrently or sequentially. A higher likelihood of grade 3/4 adverse events in melanoma has been linked to the combination of dabrafenib, trametinib, and anti-PD-1 treatment than would be predicted with targeted therapy alone. In order to simultaneously restore and improve immune activity and foster therapeutic synergy, emerging medications are starting to adopt a more thorough view of the tumor microenvironment (TME) and are exposing complimentary strategies. In addition to refining parameters like delivery time, dose, and sequencing that may improve the therapeutic index, future research on combined therapy should continue to focus on examining the complex interactions between targeted medications and immunotherapy [17-24].

Conclusions and outlooks for the future. One of the most studied and clinically evaluated cancer treatment modalities is chemotherapy. In order to give a general picture of how the field has changed over time and to track the potential and druggability of many tumors in the clinic, we have included the current state of chemotherapy and a number of medications currently used in clinical practice in this study. Creating new, more effective, and less toxic derivatives of existing medications is one of the emerging ideas in the drug discovery paradigm. It has been proposed that a number of naturally occurring chemicals that have been derived from microorganisms, plants, or other natural sources have great potential to target stress response pathways by triggering a hyperactive response that kills cancer cells [4-12]. The use of natural chemicals and agents as chemotherapeutic medications has shown various advantages over synthetic ones, including lower cytotoxicity, lower cost, and a simpler extraction and manufacture process. Therefore, a major determinant of the future success of cancer chemotherapy regimens will be the identification and mitigation of treatment toxicity. The potential for combination therapy to become a promising therapeutic technique for treating a variety of cancers in the future was further highlighted by revised clinical strategies. Combination techniques include immunotherapy, tailored medicine, targeted drug delivery, and chemotherapy regimens that clearly overlap. In addition to increasing the effectiveness of conventional treatment, it may also make some cancers more sensitive to therapeutic targeting in the clinic. Personalized combination treatments that target distinct tumor types according to their molecular characteristics may be the most promising of these. As more individualized knowledge about chemotherapeutic treatments becomes available, more focus will be placed on customized regimens that have a high chance of clinical success. Chemotherapy can thereby enhance the clinical result in combination medicines beyond its usual therapeutic efficacy. More clinical research is necessary because the implementation of these combination techniques in clinics has not yet been fully successful [14-19]. Finally, it can be said that although clinical chemotherapy for cancer has made significant progress, there is still need for improvement, especially with regard to the safety and effectiveness of various chemotherapy regimens. As a result, evaluating the effectiveness of combined treatment regimens calls for much more coordinated efforts and thorough research. To sum up, in order to increase the therapeutic efficacy of chemotherapeutic regimens in the clinic, more research effort should be put into the design of drugs for individual or combined regimens, as well as rigorous clinical studies that involve meticulous patient selection and stratification [20-26].

Discussion. Cancer patients have faced severe physical and psychological difficulties as a result of traditional therapeutic procedures including chemotherapy and radiation therapy. It is encouraging that there has been a significant and thorough change in the tumor treatment environment. Small molecule

targeted medicines, antibody-drug conjugates (ADCs), cell-based treatments, and gene therapy are becoming increasingly popular methods. In addition to offering precise and individualized tumor targeting, these state-of-the-art treatment techniques significantly improve therapeutic comfort for patients and may slow the development of the disease. However, it is recognized that many therapeutic approaches still have unrealized potential for improvement [1,2,3,8,9,10]. The development of more precise and efficient therapeutic approaches to inhibit tumor growth and metastasis is the goal of oncology medication research and development. We provide an overview of the development and use of numerous cancer medications in this article, including a variety of kinds and modes of action. The table below provides a thorough summary and comparison of various approaches by compiling the benefits, drawbacks, difficulties, and representative medications or clinical trials associated with cancer treatments included here. First, AI will permeate every facet of cancer treatment. The main goal of current research is to employ AI in healthcare to enable automated tissue pathology diagnosis. A research evaluating the diagnostic ability of GPT-4 with complex medical information was published in JAMA in June 2023. Results showed that GPT-4 provided accurate potential diagnoses in two-thirds of cases and correctly recognized the primary diagnosis in over 40% of cases [9-15]. New approaches to tumor treatment are being guided by the molecular principles underlying cancer heterogeneity that have been revealed by multi-omics research. Currently, preclinical research is doing a number of omics investigations, including CODEX (CO-Detection by IndEXing), TOF mass spectrometry, and spatial omics. By combining spatial resolution and molecular characterisation, these multi-omics technologies allow for the spatial organization of tumor microenvironments and the dissection of tumor molecular structures. Tumor samples have been subjected to slide-DNA-seq, which enables the spatial resolution of genetic information within intact tissue samples. Novel medications based on how the gut microbiome affects the development of tumors. The gastrointestinal tract serves as a home for viruses, fungi, and bacteria. There have been reports linking the gut microbiota to the occurrence and progression of numerous malignancies as well as the effectiveness of immunotherapy for them. Helicobacter spp., linked to primary liver cancer and gastric cancer, and Salmonella typhi, linked to gallbladder cancer, are known intestinal carcinogenic bacteria. The World Health Organization has classified Helicobacter as a Group 1 carcinogen [16-24]. Acquiring a thorough grasp of the benefits and drawbacks of these therapeutic approaches could lead to new insights for clinical practice and fundamental research projects. The many treatment techniques, such as cell therapy, gene therapy, peptide and antibody medicines, and small molecule targeted medications, were covered in this review. It will give a thorough overview of each approach, covering its current state of development, potential solutions, and clinical difficulties. The goal is to help researchers and doctors better understand these many therapy alternatives so they may conduct more effective treatment and make greater progress on their studies. These findings also shown how carcinogenic bacteria affect the makeup of primary immune treatment resistance. In conclusion, investigations on gut microbiota are crucial for cancer prevention and therapy, as recent research has demonstrated a strong correlation between gut microbiota and the development and spread of malignancies [1,2,3,11,15,17,19].

Conclusions. All things considered, cancer treatment will be more varied and integrated in the future, mixing cutting-edge technologies with conventional therapeutic approaches to give patients more options. We will be better prepared to face this challenge and eventually accomplish the control and cure of cancer as our comprehension of its complexity grows.

These findings also shown how the makeup of initial resistance to immune treatment is influenced by carcinogenic bacteria. To sum up, recent studies have demonstrated a strong correlation between gut microbiota and the development and spread of cancers, and research on gut microbiota is crucial for both cancer prevention and treatment.

In conclusion, clinical chemotherapy for cancer has made significant progress, but there is still need for improvement, especially with regard to the safety and effectiveness of new chemotherapeutic regimens. As a result, it also calls for coordinated efforts and thorough research to evaluate the effectiveness of combined treatment regimens. To sum up, in order to increase the therapeutic efficacy of

chemotherapeutic regimens in the clinic, more research should be done on drug design in individual or combined regimes and clinical trials should be conducted rigorously with thorough patient selection and stratification.

References.

1. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J, Pérez de la Lastra JM. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022 Mar 18;10(4):1367-1401. doi: 10.1016/j.gendis.2022.02.007.
2. Janssen L.M.E., Ramsay E.E., Logsdon C.D., Overwijk W.W. The immune system in cancer metastasis: friend or foe? J Immunother Cancer. 2017;5(1):79. doi: 10.1186/s40425-017-0283-9.
3. Laplagne C., Domagala M., le Naour A., et al. Latest advances in targeting the tumor microenvironment for tumor suppression. Int J Mol Sci. 2019;20(19):4719. doi: 10.3390/ijms20194719.
4. Emon B., Bauer J., Jain Y., Jung B., Saif T. Biophysics of tumor microenvironment and cancer metastasis - a mini review. Comput Struct Biotechnol J. 2018;16:279–287. doi: 10.1016/j.csbj.2018.07.003.
5. Costa A., Scholer-Dahirel A., Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin Cancer Biol. 2014;25:23–32. doi: 10.1016/j.semcancer.2013.12.007.
6. Gilbert S., Oliphant C., Hassan S., et al. ATP in the tumour microenvironment drives expression of nfP2X7, a key mediator of cancer cell survival. Oncogene. 2019;38(2):194–208. doi: 10.1038/s41388-018-0426-6.
7. Pfirschke C., Siwicki M., Liao H.W., Pittet M.J. Tumor microenvironment: no effector T cells without dendritic cells. Cancer Cell. 2017;31(5):614–615. doi: 10.1016/j.ccell.2017.04.007.
8. Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy. [Updated 2023 Feb 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564367/
9. DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008 Nov 01;68(21):8643-53.
10. Liu, B., Zhou, H., Tan, L. et al. Exploring treatment options in cancer: tumor treatment strategies. Sig Transduct Target Ther 9, 175 (2024). https://doi.org/10.1038/s41392-024-01856-7
11. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca. Cancer J. Clin. 71, 209–249 (2021).
12. Worldwide cancer statistics. Cancer Research UK https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer (2015).
13. Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101–126 (2023).
14. Sun, X. et al. Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination. Cell Death Dis. 14, 839 (2023).
15. Bedoui S., Herold M.J., Strasser A. Emerging connectivity of programmed cell death pathways and its physiological implications. Nat Rev Mol Cell Biol. 2020;21(11):678–695. doi: 10.1038/s41580-020-0270-8.

16. Rodrigues D., Souza T., Jennen D.G.J., Lemmens L., Kleinjans J.C.S., de Kok T.M. Drug-induced gene expression profile changes in relation to intestinal toxicity: state-of-the-art and new approaches. Cancer Treat Rev. 2019;77:57–66. doi: 10.1016/j.ctrv.2019.06.004.
17. Delou J.M.A., Souza A.S.O., Souza L.C.M., Borges H.L. Highlights in resistance mechanism pathways for combination therapy. Cells. 2019;8(9):1013. doi: 10.3390/cells8091013.
18. di Lonardo A., Nasi S., Pulciani S. Cancer: we should not forget the past. J Cancer. 2015;6(1):29–39. doi: 10.7150/jca.10336
19. Lee C.T., Huang Y.W., Yang C.H., Huang K.S. Drug delivery systems and combination therapy by using Vinca alkaloids. Curr Top Med Chem. 2015;15(15):1491–1500. doi: 10.2174/1568026615666150414120547.
20. Kalra R.S., Chaudhary A., Yoon A.R., et al. CARF enrichment promotes epithelial-mesenchymal transition via Wnt/β-catenin signaling: its clinical relevance and potential as a therapeutic target. Oncogenesis. 2018;7(5):39. doi: 10.1038/s41389-018-0048-4
21. Sun, H. et al. TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC. Cell Death Dis. 13, 450 (2022).
22. Falzone, L., Salomone, S. & Libra, M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol. 9, 1300 (2018).
23. Lemberg, K. M., Gori, S. S., Tsukamoto, T., Rais, R. & Slusher, B. S. Clinical development of metabolic inhibitors for oncology. J. Clin. Invest. 132, e148550 (2022).
24. Dhakal, A., Gyawali, R., Wang, L. & Cheng, J. A large expert-curated cryo-EM image dataset for machine learning protein particle picking. Sci. Data 10, 392 (2023).
25. Skalidis, I. et al. Cryo-EM and artificial intelligence visualize endogenous protein community members. Struct. Lond. Engl. 30, 575–589.e6 (2022).
26. Jänne, P. A. et al. Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N. Engl. J. Med. 387, 120–131 (2022).